CEACAM5 and neoplasm: From as early as 1978 investigators were examining the prognostic value of CEA in patients receiving endocrine therapy for the treatment of metastatic breast cancer (MBC) [5], but the value of tumour markers in monitoring response to fulvestrant ('Faslodex') treatment has not previously been evaluated.